Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

Report Code: BIO071C

Publish Date: Sep 2014

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for nucleic acid aptamers reached $340.5 million in 2014. This market should grow to about $610.3 million in 2015 and about $5.4 billion in 2019, with a compound annual growth rate (CAGR) of 73.5% from 2014 to 2019.

Report Includes

  • An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2019
  • Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
  • Examination of high growth and market potential segments of the industry, and new and established companies in the arena
  • Comprehensive company profiles of major players in the industry.

Report Scope

This research report presents an in-depth analysis of the global nucleic acid aptamer market by technologies, applications and geographic regional markets. It includes key technologies involved, analyzes the capabilities and characteristics of aptamers in comparison with antibodies and lists specific areas where aptamers could find application. The evolving trends and technological developments in the field of aptamers have been studied in detail.

Special emphasis will be given to collaborative efforts, research innovations and investment clinical trials conducted. Patents will be discussed as well. This study also analyzes the aptamer-based drugs that have been developed or are in the pipeline for the treatment of various diseases. Impact analysis of the key drivers and factors affecting or influencing the growth of this market is also included.

The market for aptamer technologies is further categorized into enabling technology, diagnostic sensors and therapeutics. Enabling technology consists of SELEX technology, modified oligonucleotides, next-generation sequencing, nanoparticles and quantum dot labels, surface plasmon resonance and biolayer interferometry and bioinformatics. In terms of application the market is classified into diagnostics, therapeutics, research, biosensors, biomarker discovery and others.

Furthermore, diagnostics-based aptamers are used in environmental monitoring and food and water safety. They are also used for developing aptasensors for sensing small molecules and pathogens. Aptamers also find application in human clinical diagnostic assays for diagnosing diseases such as cancer, infectious diseases and other immunological diseases.

Aptamers are used in therapeutics and research as drug delivery vehicles in cancer, as a modifier of surgical implants and in bioseparation processes. Research areas include flow cytometry, mass spectrometry and Western blotting; they are also used as reagents and assays and as biosensors and biomarker molecules.

The market is segmented by regions into North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Ophthotech Corp., Alimera Sciences, AM Biotechnologies LLC, Alnylam Pharmaceuticals, Noxxon, Rina Gmbh, Regado Biosciences, Base Pair Biotechnologies Inc., Aptamer Sciences Inc., Aptasol (Aptamer Solutions) Ltd, Isis Pharmaceuticals, Neoventures Biotechnology Inc., Mitsui & Co. (U.S.A.) Inc., Quest Diagnostics, SomaLogic Inc. and Sumitomo Bakelite Co. Ltd.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Analyst Credentials

Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life sciences market, and in the chemical domain. She has frequently delivered research services that contain strategic recommendations and top business strategies to help market players make strategic decision. She holds an MBA in Marketing.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets122Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: EXECUTIVE SUMMARY3Free
Chapter- 3: OVERVIEW31Free
Chapter- 4: NUCLEIC ACID APTAMERS MARKET BY TECHNOLOGIES15Free
Chapter- 5: NUCLEIC ACID APTAMERS MARKET BY APPLICATION28Free
Chapter- 6: NUCLEIC ACID APTAMER MARKET BY REGION5Free
Chapter- 7: COMPETITIVE LANDSCAPE11Free
Chapter- 8: PATENT ANALYSIS5Free
Chapter- 9: C. CRAMER & CO. GMBH18Free
Chapter- 10: APPENDIX3Free
Published - Oct-2012| Analyst - George W. Jackson| Code - BIO071B

Report Highlights

The global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.

Report Includes

  • An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
  • Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
  • Examination of high growth and market potential segments of the industry, and new and established companies in the arena
  • Comprehensive company profiles of major players in the industry.
Published - Mar-2010| Analyst - George W. Jackson| Code - BIO071A

Report Highlights

  • The global market for aptamers is poised for significant new market entrants in the near future. In 2009 this market was valued at $10 million. By 2014, this market is estimated to be worth $1.9 billion, a compound annual growth rate (CAGR) of nearly 68%.
  • Aptamer therapeutic markets were valued at $10 million in 2009 and should increase at a 55% compound annual growth rate (CAGR) to $1.2 billion in 2014.
  • Aptamer diagnostic markets were worth $26 million in 2010 and are expected to increase in value to $659 million in 2014, a compound annual growth rate (CAGR) of 124%.

Related Reports

Global Biochip Markets: Microarrays and Lab-on-a-Chip

Published - Oct 2013 | Publisher - John Bergin | Code - BIO049E

The global biochip products market reached $3.3 billion in 2012. This market is expected to grow to nearly $3.9 billion in 2013 and $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 30% for the five-year period 2013 to 2018.

Molecular Diagnostics: Technologies and Global Markets

Published - Mar 2013 | Publisher - Jon Evans | Code - BIO063B

In 2012, the global DNA diagnostics market was valued at $17.3 billion. The total market is projected to reach $20.1 billion in 2013 and nearly $36.5 billion by 2018, increasing at a compound annual growth rate (CAGR) of 12.6% from 2013 through 2018. 

Antibody Drugs: Technologies and Global Markets

Published - Feb 2012 | Publisher - Esther Bosklopper | Code - BIO016H

The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011.  With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.

Recent Reports

Artificial Intelligence (AI) in Cancer

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO196B

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Induced Pluripotent Stem Cells: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO135F

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.

Commercial Amino Acids

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO007N

The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Customize Report